Market Overview:
The global Huntington’s disease treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of Huntington’s disease, rising awareness about available treatments, and growing demand for better and more effective therapies. The global Huntington’s disease treatment market is segmented on the basis of type into symptomatic therapy and disease-modifying therapy. The symptomatic therapy segment is further sub-segmented into pharmacological therapies and non-pharmacological therapies. The pharmacological therapies sub-segment includes drugs such as tetrabenazine, deutetrabenazine, valbenazine, etc., which are used to treat chorea (involuntary movements), rigidity (stiffness), bradykinesia (slowness of movement), and dystonia (muscle spasms). On the other hand, non-pharmacological therapies include surgical procedures such as deep brain stimulation (DBS) and pallidotomy; these are used to treat motor symptoms in patients with advanced stages of Huntington’s disease. On the basis of application, the global Huntington’s disease treatment market is segmented into hospitals and ambulatory surgical centers.
Product Definition:
A Huntington’s disease treatment is a medication or therapy that is used to help manage the symptoms of Huntington’s disease. Treatment may include medications to help control movement problems, mood swings and cognitive decline, as well as therapies such as physical therapy and speech therapy. It is important for people with Huntington’s disease to seek treatment for their symptoms in order to maintain their quality of life.
Symptomatic Therapy:
Huntington's disease (HD) is a neurodegenerative disorder characterized by the combination of motor, cognitive, and psychiatric symptoms. HD accounts for approximately 30,000 cases annually in U.S., affecting 1 in 4,000 people annually according to the National Institute of Neurological Disorders and Stroke (NINDS). The prevalence rate is expected to rise over the forecast period due to an increase in life expectancy along with growing diagnostic criteria.
Disease-Modifying Therapy:
Disease-modifying therapy is a medical procedure that modifies or eliminates the effects of one or more disease conditions. Disease-modifying therapies are used to treat several neurological disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease and Huntington’s Chorea. Currently there are two drugs approved by the U.S Food and Drug Administration (FDA) for modifying the symptoms of Huntington’s Chorea; Namenda and Exelon Patch.
Application Insights:
The hospitals segment held the largest share of 60.0% in 2017. The application of HD patients is generally better managed in hospital settings as compared to that at home, thus accounting for a larger share in the overall revenue generation. In addition, there are fewer treatment options available for Huntington's disease at ambulatory surgical centers as compared to hospitals, which may hamper market growth over the forecast period.
On the other hand, disease-modifying therapies hold a smaller market share and are expected to witness lucrative growth during the forecast period owing to their high cost and unavailability outside clinical trials settings.
Regional Analysis:
North America dominated the global market in 2017. The presence of key pharmaceutical companies, increased healthcare expenditure, and favorable reimbursement policies are some of the factors responsible for North America’s dominance. In addition, a rise in prevalence is also expected to drive regional growth over the forecast period. According to statistics published by National Institute of Neurological Disorders & Strokes (NINDS), approximately 30,000 people are diagnosed with HD annually in U.S.
Asia Pacific region accounted for over 20% share owing to increasing prevalence coupled with rising awareness about Huntington's disease treatment options among patients especially in developing countries such as India.
Growth Factors:
- Increasing prevalence of Huntington’s Disease
- Growing awareness about Huntington’s Disease Treatment options
- Rising demand for better and more effective treatments for Huntington’s Disease
- Technological advancements in the field of Huntington’s Disease Treatment
- Availability of government funding and support for research on Huntington’s Disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Huntington’s Disease Treatment Market Research Report
By Type
Symptomatic Therapy, Disease-Modifying Therapy
By Application
Hospitals, Ambulatory Surgical Centers
By Companies
Bausch Health, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Huntington’s Disease Treatment Market Report Segments:
The global Huntington’s Disease Treatment market is segmented on the basis of:
Types
Symptomatic Therapy, Disease-Modifying Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bausch Health
- Teva Pharmaceuticals
- Wave Life Sciences
- Ionis Pharmaceuticals/ Roche
- Raptor Pharmaceuticals
- Prana Biotechnology
Highlights of The Huntington’s Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Symptomatic Therapy
- Disease-Modifying Therapy
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Huntington’s Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Huntington's Disease, but there are treatments that can help manage the symptoms. Treatment options may include medication, therapy, and surgery.
Some of the key players operating in the huntington’s disease treatment market are Bausch Health, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Huntington’s Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Huntington’s Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Huntington’s Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Huntington’s Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Huntington’s Disease Treatment Market Size & Forecast, 2020-2028
4.5.1 Huntington’s Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Huntington’s Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Symptomatic Therapy
5.2.2 Disease-Modifying Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Huntington’s Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Huntington’s Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Symptomatic Therapy
9.6.2 Disease-Modifying Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Symptomatic Therapy
10.6.2 Disease-Modifying Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Symptomatic Therapy
11.6.2 Disease-Modifying Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Symptomatic Therapy
12.6.2 Disease-Modifying Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Symptomatic Therapy
13.6.2 Disease-Modifying Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Huntington’s Disease Treatment Market: Competitive Dashboard
14.2 Global Huntington’s Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bausch Health
14.3.2 Teva Pharmaceuticals
14.3.3 Wave Life Sciences
14.3.4 Ionis Pharmaceuticals/ Roche
14.3.5 Raptor Pharmaceuticals
14.3.6 Prana Biotechnology
